Global Angiotensin Receptor Blockers (ARBs) Market Size and Forecast 2024-2033|Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company

The Angiotensin Receptor Blockers (ARBs) by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Angiotensin Receptor Blockers (ARBs) Market:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

According to The Business Research Company’s Angiotensin Receptor Blockers (ARBs), The angiotensin receptor blockers (arbs) market size has grown steadily in recent years. It will grow from $8.26 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%.  The  growth in the historic period can be attributed to hypertension epidemic, clinical efficacy, cardiovascular disease burden, renal protection, clinical guidelines, arbs as first-line treatment, cost-effectiveness.

The angiotensin receptor blockers (arbs) market size is expected to see steady growth in the next few years. It will grow to $10.28 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%.  The growth in the forecast period can be attributed to precision medicine approaches, focus on combination therapies, global expansion of market, biomarker-based treatment strategies, government initiatives, increased awareness of hypertension.. Major trends in the forecast period include telemedicine adoption, research and development investments, generic competition and patent expirations, digital health solutions for medication adherence, biosimilar competition.

The increasing incidence of cardiovascular diseases is expected to propel the growth of the angiotensin receptor blockers market going forward. Cardiovascular disease (CVD) is any condition affecting the heart or blood vessels. It is frequently associated with the development of fatty deposits within the arteries (atherosclerosis) and an increased risk of blood clots. Angiotensin receptor blockers lower blood pressure and improve the heart’s capacity to pump blood by helping in vein and artery relaxation, which can minimize the risk of cardiovascular disease. For instance, in August 2022, according to the American College of Cardiology, a US-based professional medical organization, the expected rates of cardiovascular risk factors and disease will considerably rise in the United States by the year 2060. Therefore, the increasing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Product innovation is a key trend in gaining popularity in the angiotensin receptor blockers market. Major companies operating in the angiotensin receptor blocker market are focused on developing innovative solutions to strengthen their position in the market. For instance, in February 2021, Novartis AG, a Switzerland-based pharmaceutical company, launched Entresto (sacubitril/valsartan). Entresto (sacubitril/valsartan) has been granted an expanded indication by the United States Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. The clinical benefits are most noticeable in patients with a lower-than-normal left ventricular ejection fraction (LVEF). Entresto is the first and only therapy approved in the United States to treat patients with guideline-defined heart failure, which includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).

The angiotensin receptor blockers (arbs) market report table of contents includes:

1. Executive Summary

2. Angiotensin Receptor Blockers (ARBs) Market Characteristics

3. Angiotensin Receptor Blockers (ARBs) Market Trends And Strategies

4. Angiotensin Receptor Blockers (ARBs) Market – Macro Economic Scenario

5. Global Angiotensin Receptor Blockers (ARBs) Market Size and Growth

.

.

.

26. South America Angiotensin Receptor Blockers (ARBs) Market

27. Brazil Angiotensin Receptor Blockers (ARBs) Market

28. Middle East Angiotensin Receptor Blockers (ARBs) Market

29. Africa Angiotensin Receptor Blockers (ARBs) Market

30. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape And Company Profiles

Top Major Players:

• Pfizer Inc
• Novartis AG
• Merck & Co. Inc
• AstraZeneca Plc
• Bristol-Myers Squibb Company

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model